Get the Stockscreener App
6.97
16.02%
-1.33
Champions Oncology Inc stock is traded at $6.97, with a volume of 137.87K.
It is down -16.02% in the last 24 hours and up +6.90% over the past month.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
See More
Previous Close:
$8.30
Open:
$6.92
24h Volume:
137.87K
Relative Volume:
3.71
Market Cap:
$96.11M
Revenue:
$49.98M
Net Income/Loss:
$-9.64M
P/E Ratio:
-9.8169
EPS:
-0.71
Net Cash Flow:
$-4.86M
1W Performance:
+5.45%
1M Performance:
+6.90%
6M Performance:
-24.49%
1Y Performance:
+39.40%
1-Day Range:
$6.86
$7.6336
1-Week Range:
$6.325
$8.74
52-Week Range:
$3.75
$11.99
Champions Oncology Inc Stock (CSBR) Company Profile
Name
Champions Oncology Inc
Sector
Industry
Phone
410-369-0365
Address
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
6.97 | 114.44M | 49.98M | -9.64M | -4.86M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.36 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.24 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.06 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
752.32 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.20 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-18-19 | Initiated | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Stock (CSBR) Latest News
How sentiment analysis helps forecast Champions Oncology Inc.Weekly Profit Summary & Stepwise Trade Execution Plans - newser.com
Is Champions Oncology Inc. stock ready for a breakout2025 Market Sentiment & Community Consensus Trade Alerts - newser.com
How to monitor Champions Oncology Inc. with trend dashboardsQuarterly Earnings Summary & Precise Buy Zone Identification - newser.com
The Market Lifts Champions Oncology, Inc. (NASDAQ:CSBR) Shares 27% But It Can Do More - simplywall.st
Champions Oncology Reports Steady Revenue and New Leadership - TipRanks
Champions Oncology Inc (CSBR) Q1 2026 Earnings Call Highlights: Revenue Rebound and Strategic ... By GuruFocus - Investing.com Canada
Live market analysis of Champions Oncology Inc.Weekly Trade Report & Verified Chart Pattern Signals - newser.com
Guidance Update: Will Champions Oncology Inc benefit from geopolitical trendsVolume Spike & Real-Time Stock Movement Alerts - خودرو بانک
Movement Recap: Is Champions Oncology Inc showing insider buyingQuarterly Profit Report & Accurate Entry and Exit Point Alerts - خودرو بانک
Earnings call transcript: Champions Oncology Q1 2026 beats EPS expectations - Investing.com
Aug Technicals: Does Champions Oncology Inc have strong fundamentalsStop Loss & Risk Managed Investment Strategies - خودرو بانک
Champions Oncology Inc reports results for the quarter ended July 31Earnings Summary - TradingView
Champions Oncology falls after slight revenue miss in first quarter By Investing.com - Investing.com Nigeria
Champions Oncology falls after slight revenue miss in first quarter - Investing.com
Champions Oncology Reports Quarterly Revenue of $14.0 Million - TradingView
CHAMPIONS ONCOLOGY, INC. SEC 10-Q Report - TradingView
CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million - ACCESS Newswire
Oncology Research Leader Champions Reports $14M Revenue as New CEO Rob Brainin Sets Growth Strategy - Stock Titan
Champions Oncology Reports Record Quarterly Revenue of $14.0 Million - ACCESS Newswire
Oncology Research Leader Champions Reports $14M Revenue as New CEO Rob Brainin Charts Growth Strategy - Stock Titan
How to interpret RSI for Champions Oncology Inc. stockWeekly Profit Report & Long-Term Capital Growth Ideas - newser.com
Bank Watch: Does Champions Oncology Inc stock have upside surprise potential2025 Winners & Losers & Low Drawdown Investment Strategies - خودرو بانک
Is Champions Oncology Inc. forming a bottoming baseJuly 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
is champions oncology inc. stock ready for a breakoutMarket Trend Review & Safe Capital Preservation Plans - newser.com
Will Champions Oncology Inc. stock recover after recent dropMarket Growth Report & Weekly High Potential Stock Alerts - newser.com
Using flow based indicators on Champions Oncology Inc.Quarterly Market Review & Verified Technical Trade Signals - newser.com
Advanced analytics toolkit walkthrough for Champions Oncology Inc.Quarterly Market Summary & Weekly Stock Breakout Alerts - newser.com
Smart tools for monitoring Champions Oncology Inc.’s price actionJuly 2025 Retail & Advanced Technical Signal Analysis - Newser
Tools to monitor Champions Oncology Inc. recovery probabilityDollar Strength & Fast Gain Stock Trading Tips - Newser
Visual trend scoring systems applied to Champions Oncology Inc.July 2025 Action & AI Enhanced Trading Alerts - Newser
Will Champions Oncology Inc. stock outperform value stocksJuly 2025 Intraday Action & Community Shared Stock Ideas - baoquankhu1.vn
Champions Oncology Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Champions Oncology Inc. stock prediction for this week2025 Technical Overview & Stepwise Trade Signal Implementation - Newser
Will Champions Oncology Inc. price bounce be sustainableMarket Trend Summary & Daily Momentum Trading Reports - Newser
Can Champions Oncology Inc. recover in the next quarterJuly 2025 Catalysts & Verified Momentum Stock Ideas - Newser
Technical signs of recovery in Champions Oncology Inc.Portfolio Value Report & Fast Moving Stock Trade Plans - Newser
Chart based analysis of Champions Oncology Inc. trends2025 Biggest Moves & AI Powered Buy and Sell Recommendations - Newser
What momentum shifts mean for Champions Oncology Inc.2025 Bull vs Bear & AI Forecasted Stock Moves - Newser
Signal strength of Champions Oncology Inc. stock in tech scannersWeekly Earnings Recap & Risk Adjusted Buy/Sell Alerts - Newser
Using economic indicators to assess Champions Oncology Inc. potential2025 Earnings Impact & Capital Protection Trading Alerts - Newser
Visualizing Champions Oncology Inc. stock with heatmaps2025 Dividend Review & Breakout Confirmation Trade Signals - Newser
Champions Oncology Inc Stock (CSBR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):